Corbus Pharmaceuticals Holdings, Inc. (0SZI.L)
USD 14.17
(-0.14%)
USD 14.17
(-0.14%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 13.9 Million USD | -60.07% |
| 2022 | 34.83 Million USD | -38.75% |
| 2021 | 56.87 Million USD | -55.13% |
| 2020 | 126.74 Million USD | 11.92% |
| 2019 | 113.24 Million USD | 83.93% |
| 2018 | 61.56 Million USD | 75.9% |
| 2017 | 35 Million USD | 59.86% |
| 2016 | 21.89 Million USD | 130.44% |
| 2015 | 9.5 Million USD | 258.95% |
| 2014 | 2.64 Million USD | 375.02% |
| 2013 | 557.27 Thousand USD | 67267.57% |
| 2012 | 827.22 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 9.47 Million USD | -4.86% |
| 2024 Q2 | 10.78 Million USD | 13.9% |
| 2023 Q1 | 17.29 Million USD | 60.2% |
| 2023 FY | 44.43 Million USD | 27.56% |
| 2023 Q4 | 9.95 Million USD | 4.93% |
| 2023 Q3 | 9.48 Million USD | 15.86% |
| 2023 Q2 | 8.18 Million USD | -52.66% |
| 2022 Q4 | 10.79 Million USD | 31.97% |
| 2022 Q3 | 8.18 Million USD | 11.46% |
| 2022 Q2 | 7.34 Million USD | -13.82% |
| 2022 Q1 | 8.51 Million USD | -14.81% |
| 2022 FY | 34.83 Million USD | -38.75% |
| 2021 Q1 | 16.06 Million USD | -25.19% |
| 2021 Q2 | 16.83 Million USD | 4.83% |
| 2021 Q3 | 13.97 Million USD | -17.01% |
| 2021 FY | 56.87 Million USD | -55.13% |
| 2021 Q4 | 9.99 Million USD | -28.44% |
| 2020 Q3 | 35.2 Million USD | -8.38% |
| 2020 Q2 | 38.42 Million USD | 21.42% |
| 2020 Q1 | 31.64 Million USD | 6.33% |
| 2020 FY | 126.74 Million USD | 11.92% |
| 2020 Q4 | 21.47 Million USD | -39.01% |
| 2019 Q3 | 27.68 Million USD | 1.08% |
| 2019 FY | 113.24 Million USD | 83.93% |
| 2019 Q1 | 28.4 Million USD | 45.55% |
| 2019 Q4 | 29.76 Million USD | 7.5% |
| 2019 Q2 | 27.38 Million USD | -3.59% |
| 2018 Q2 | 13.24 Million USD | 3.37% |
| 2018 Q1 | 12.81 Million USD | 17.98% |
| 2018 FY | 61.56 Million USD | 75.9% |
| 2018 Q4 | 19.51 Million USD | 22.07% |
| 2018 Q3 | 15.98 Million USD | 20.69% |
| 2017 Q3 | 7.75 Million USD | 1.46% |
| 2017 FY | 35 Million USD | 59.86% |
| 2017 Q2 | 7.64 Million USD | -12.63% |
| 2017 Q4 | 10.86 Million USD | 40.1% |
| 2017 Q1 | 8.74 Million USD | 10.04% |
| 2016 Q3 | 6.07 Million USD | 32.43% |
| 2016 FY | 21.89 Million USD | 130.44% |
| 2016 Q4 | 7.94 Million USD | 30.8% |
| 2016 Q2 | 4.58 Million USD | 39.72% |
| 2016 Q1 | 3.28 Million USD | 14.62% |
| 2015 Q4 | 2.86 Million USD | 18.13% |
| 2015 Q2 | 2.67 Million USD | 74.32% |
| 2015 Q1 | 1.53 Million USD | 21.94% |
| 2015 FY | 9.5 Million USD | 258.95% |
| 2015 Q3 | 2.42 Million USD | -9.38% |
| 2014 Q4 | 1.25 Million USD | 53.88% |
| 2014 FY | 2.64 Million USD | 375.02% |
| 2014 Q3 | 818.2 Thousand USD | 76.22% |
| 2014 Q2 | 464.29 Thousand USD | 339.49% |
| 2014 Q1 | 105.64 Thousand USD | -61.76% |
| 2013 Q3 | 45.34 Thousand USD | -76.97% |
| 2013 Q1 | 34.65 USD | 0.0% |
| 2013 Q2 | 196.9 Thousand USD | 568111.46% |
| 2013 Q4 | 276.25 Thousand USD | 509.23% |
| 2013 FY | 557.27 Thousand USD | 67267.57% |
| 2012 FY | 827.22 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Editas Medicine, Inc. | 247.3 Million USD | 94.375% |
| Dynavax Technologies Corporation | 219.14 Million USD | 93.653% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 97.371% |
| Perrigo Company plc | 1.52 Billion USD | 99.09% |
| Illumina, Inc. | 3.81 Billion USD | 99.635% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 99.864% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 96.916% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.966% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 99.322% |
| Heron Therapeutics, Inc. | 120.65 Million USD | 88.472% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 99.506% |
| Unity Biotechnology, Inc. | 44.66 Million USD | 68.859% |
| Waters Corporation | 943.51 Million USD | 98.526% |
| Biogen Inc. | 5.2 Billion USD | 99.733% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 93.917% |
| Evolus, Inc. | 189.75 Million USD | 92.67% |
| Adicet Bio, Inc. | 152.03 Million USD | 90.851% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 90.236% |
| bluebird bio, Inc. | 240.23 Million USD | 94.21% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 94.884% |
| FibroGen, Inc. | 398.11 Million USD | 96.506% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 99.342% |
| Homology Medicines, Inc. | 9.87 Million USD | -40.857% |
| Geron Corporation | 70.44 Million USD | 80.253% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 99.227% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 96.747% |
| Myriad Genetics, Inc. | 600.1 Million USD | 97.682% |
| Viking Therapeutics, Inc. | 100.82 Million USD | 86.204% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 97.478% |
| Zoetis Inc. | 2.76 Billion USD | 99.497% |
| Abeona Therapeutics Inc. | 48.5 Million USD | 71.322% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 98.723% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 99.203% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 99.709% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | 64.474% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 98.216% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 94.955% |
| Verastem, Inc. | 92.08 Million USD | 84.895% |
| Nektar Therapeutics | 190.9 Million USD | 92.714% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 97.08% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -14.568% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 98.978% |
| OPKO Health, Inc. | 574.68 Million USD | 97.58% |
| Exelixis, Inc. | 1.58 Billion USD | 99.123% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 99.129% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 96.226% |
| Anavex Life Sciences Corp. | 55.75 Million USD | 75.053% |
| uniQure N.V. | 285.08 Million USD | 95.121% |
| Imunon, Inc. | 21.03 Million USD | 33.859% |
| Blueprint Medicines Corporation | 722.86 Million USD | 98.076% |
| Insmed Incorporated | 949.26 Million USD | 98.535% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 95.353% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 96.597% |
| TG Therapeutics, Inc. | 198.47 Million USD | 92.992% |
| Incyte Corporation | 1.19 Billion USD | 98.832% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 98.668% |